truscreen®
a world without cervical cancer



NZX/ASX Announcement

27 November 2026

Change of Reporting Date

Truscreen Group Limited (NZX/ASX: TRU) (TruScreen or Company) advises that it will change its reporting date from 31 March to 30 June.

This change reflects the following;

(a) TRU's business is substantially in Asia with a growing distribution network in Africa. Chinese New Year (in China and Vietnam) and Ramadan (in Indonesia, Africa and parts of India) generally fall in February, and TRU's distributors and their customers take leave before, during and after those periods. This creates uncertainty around revenue recognition and business operations in the fourth quarter of TRU's current financial year (i.e. immediately before the Current Balance Date). A 30 June balance date moves TRU's year end away from this period and allow the reporting cycle to be in synch with its business cycle; and

(b) TRU's core subsidiary and employees are based in Australia and work to a 30 June year end. The New Balance Date will align TRU's reporting with its Australian operations.

A move to 30 June enables the Company to give its shareholders clear guidance on performance and remove the volatility around trading in the final quarter of the financial year.

The Company will release a full Interim Report for the 9 months ended 31 December 2026 and a full year Annual report for the 15 months ended 30 June 2026.

All companies in the group will adopt a 30 June year end.

The Company provides the following information in relation to performance in the six months to 30 September 2026.

	30 September 2026	*30 September 2025*	*% Change*
	$	$	
Revenue from sale of goods	547,567	860,795	(36%)
Total Revenue	840,645	993,999	(15%)
Loss before income tax	(1,666,449)	(1,358,451)	Loss +22.7%
Basic and diluted loss per share (cents)	(0.17)	(0.19)	(10.5%)
Cash and Cash Equivalents	3,892,069	2,238,785	74%
Net assets	5,013,699	3,376,342	48%
Net tangible assets per share (cents)	0.47	0.45	4%
Net cash used in operations	(1,134,661)	(1,694,048)	33%
Shares on issue	1,047,718,877	747,325,326	40%

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia

CE ISO 13485 NATIONAL MEDICAL PRODUCTS ADMINISTRATION 国家药品监督管理局

truscreen®
a world without cervical cancer



Revenue for the half year was 15% down over the prior period at $0.84 million, with China buying a shipment of SUS prior to Chinese New Year and is now re-aligning its inventory of SUS in early FY2027. China is also encountering lower economic growth and consumer confidence from global geopolitical influences. The Company reported an operating loss of NZ$1.67 million (1H FY2026: NZ$1.36 million), which included a non-cash charge of $0.25 million relating to share based incentives.

Net operating cash outflow was NZ$1.1 million (1H FY2026: NZ$1.7 million).

As at 30 September 2026, the Company had cash and cash equivalents of NZ$3.9 million.

Authorised by the Board for filing with the NZX/ASX.

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

truscreen®
a world without cervical cancer



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures

an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".
To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia

CE ISO 13485 NATIONAL MEDICAL PRODUCTS ADMINISTRATION 国家药品监督管理局